Nanobiotix 2018 Annual Results

World News: . []

             Philippe Mauberna, Chief Financial Officer of Nanobiotix said: “.”

The unaudited consolidated financial statements for the fiscal year ended December 31, 2018 were approved by the executive board and reviewed by the supervisory board of the Company on March 15, 2019.

Total headcount on a consolidated basis reached 102 as of December 31, 2018 vs. 85 as of December 31, 2017, in line with the Company’s growth.

Net loss after tax amounts to €30.3M as of December 31, 2018 (vs. €26.1M loss as of December 31, 2017).

                Nanobiotix presented initial promising data from Phase I/II Liver trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors at the American Society of Clinical Gastrointestinal annual meeting (ASCO GI). These positive results show that NBTXR3 was well tolerated with no adverse event related to NBTXR3 and no dose-limiting toxicity.

                Nanobiotix and the University of Texas MD Anderson Cancer Center have an agreement to run immunotherapeutic pre-clinical research in lung cancer. The main objectives of this project, with one of the world’s leading oncology research centers, is to provide preclinical data using NBTXR3 activated by radiotherapy plus anti PD-1 Nivolumab (murine version of Opdivo™).

                Nanobiotix and Weill Cornell Medicine partnered to perform pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers. The main objective is to study the impact of NBTXR3 activated by radiotherapy on cGAS-STING, a key component of the anti-tumor immune response. Data generated from this collaboration could provide support for the assertion that NBTXR3 activated by radiotherapy can increase the anti-tumor immune response compared to radiotherapy alone.

                This honor recognizes the best performing Tech SMEs listed on Euronext markets. An independent group of European experts annually selects 40 great companies on the basis of their business, financial and stock market performance.

                In January 2019, Nanobiotix announced that it plans to conduct a registered public offering of its ordinary shares, including the form of American Depositary Shares (ADSs) in the United States. Nanobiotix submitted a confidential draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission.

This year, Nanobiotix expects to receive its CE mark for NBTXR3 for the treatment of Soft Tissue Sarcoma, which would improve access to the product for cancer patients.In parallel, clinical development should advance with the publication of data in several cancer types.


Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.  

Nanobiotix’s first-in-class, proprietary lead technology, NanoXray, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

More news and information about NANOBIOTIX

Published By:

Globe Newswire: 17:40 GMT Friday 15th March 2019

Published: .

Search for other references to "nanobiotix" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us